Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes – exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations-Reference-Cited by-同舟云学术

Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes – exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations

Published:2020-11-02 Issue:12 Volume:36 Page:1985-1989
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Alshnbari Afnan¹,Alkharaiji Mohammed¹²,Anyanwagu Uchenna¹,Idris Iskandar¹

Affiliation:

1. Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, Royal Derby Hospital, University of Nottingham, Derby, UK

2. Faculty of Public Health, College of Health, The Saudi Electronic University, Riyadh, Saudi Arabia

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1840340

Reference19 articles.

1. SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review

2. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System

3. Association of Diuretics Use and Amputations in Patients with Type 2 Diabetes—A Hypothesis Driven from Canvas Warning?

4. The Heath Improvement Network (THIN). 2018. Available from: https://www.iqvia.com/locations/uk-and-ireland/thin.

5. One-to-many propensity score matching in cohort studies

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of amputation under diuretics in patients with or at risk of lower extremity arterial disease: A systematic review and meta-analysis;Archives of Cardiovascular Diseases;2023-06

2. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER;European Heart Journal;2023-05-23

3. Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis;Cardiovascular Endocrinology & Metabolism;2023-05-08

4. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials;Diabetes Research and Clinical Practice;2023-04

5. SGLT2 Inhibitors and Safety in Older Patients;Heart Failure Clinics;2022-10